These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 16081189)

  • 1. TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).
    Weeratna RD; Makinen SR; McCluskie MJ; Davis HL
    Vaccine; 2005 Nov; 23(45):5263-70. PubMed ID: 16081189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination.
    Ma R; Du JL; Huang J; Wu CY
    Biochem Biophys Res Commun; 2007 Sep; 361(2):537-42. PubMed ID: 17662694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Impact of different adjuvants on immunogenicity of the HBV particle vaccine containing the S + preS1 fusion antigen in Balb/C mice].
    Chen H; Deng Y; Tan W; Wang W; Yin X; Guan J; Wang W; Ruan L
    Sheng Wu Gong Cheng Xue Bao; 2010 Jan; 26(1):74-8. PubMed ID: 20353095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of intravaginal HSV-2 infection in mice: a comparison of CpG oligodeoxynucleotides and resiquimod (R-848).
    McCluskie MJ; Cartier JL; Patrick AJ; Sajic D; Weeratna RD; Rosenthal KL; Davis HL
    Antiviral Res; 2006 Feb; 69(2):77-85. PubMed ID: 16377001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen.
    Mutwiri G; Benjamin P; Soita H; Babiuk LA
    Vaccine; 2008 May; 26(22):2680-8. PubMed ID: 18430493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model.
    Otero M; Calarota SA; Felber B; Laddy D; Pavlakis G; Boyer JD; Weiner DB
    Vaccine; 2004 Apr; 22(13-14):1782-90. PubMed ID: 15068862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CpG ODN enhances immunization effects of hepatitis B vaccine in aged mice.
    Qin W; Jiang J; Chen Q; Yang N; Wang Y; Wei X; Ou R
    Cell Mol Immunol; 2004 Apr; 1(2):148-52. PubMed ID: 16212903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant activities of immune response modifier R-848: comparison with CpG ODN.
    Vasilakos JP; Smith RM; Gibson SJ; Lindh JM; Pederson LK; Reiter MJ; Smith MH; Tomai MA
    Cell Immunol; 2000 Aug; 204(1):64-74. PubMed ID: 11006019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orally administered OVA/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice.
    Alignani D; Maletto B; Liscovsky M; Rópolo A; Morón G; Pistoresi-Palencia MC
    J Leukoc Biol; 2005 Jun; 77(6):898-905. PubMed ID: 15758079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
    Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
    Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors.
    Daftarian P; Song GY; Ali S; Faynsod M; Longmate J; Diamond DJ; Ellenhorn JD
    Cancer Res; 2004 Aug; 64(15):5407-14. PubMed ID: 15289349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [CpG oligodeoxynucleotide enhances humoral and cellular immune responses against HBsAg in mice].
    Zhou Z; Chen WS; Yao JL
    Zhonghua Nei Ke Za Zhi; 2003 Sep; 42(9):640-2. PubMed ID: 14514394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Airway peptidoglycan and immunostimulatory DNA exposures have divergent effects on the development of airway allergen hypersensitivities.
    Chisholm D; Libet L; Hayashi T; Horner AA
    J Allergy Clin Immunol; 2004 Mar; 113(3):448-54. PubMed ID: 15007346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
    Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
    Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toll-like receptor agonists allow generation of long-lasting antipneumococcal humoral immunity in response to a plain polysaccharidic vaccine.
    Taillardet M; Haffar G; Mondière P; Asensio MJ; Pléau-Pison T; Burdin N; Defrance T; Genestier L
    J Infect Dis; 2010 Aug; 202(3):470-9. PubMed ID: 20575660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CpG-ODN inhibits airway inflammation at effector phase through down-regulation of antigen-specific Th2-cell migration into lung.
    Ashino S; Wakita D; Zhang Y; Chamoto K; Kitamura H; Nishimura T
    Int Immunol; 2008 Feb; 20(2):259-66. PubMed ID: 18156622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer.
    Lubaroff DM; Karan D; Andrews MP; Acosta A; Abouassaly C; Sharma M; Krieg AM
    Vaccine; 2006 Aug; 24(35-36):6155-62. PubMed ID: 16876291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates.
    Wille-Reece U; Flynn BJ; Loré K; Koup RA; Kedl RM; Mattapallil JJ; Weiss WR; Roederer M; Seder RA
    Proc Natl Acad Sci U S A; 2005 Oct; 102(42):15190-4. PubMed ID: 16219698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of multispecific Th-1 type immune response against HCV in mice by protein immunization using CpG and Montanide ISA 720 as adjuvants.
    Qiu Q; Wang RY; Jiao X; Jin B; Sugauchi F; Grandinetti T; Alter HJ; Shih JW
    Vaccine; 2008 Oct; 26(43):5527-5534. PubMed ID: 18675871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
    Merlo A; Calcaterra C; Mènard S; Balsari A
    J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.